Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1990 Jun 15;142(12):1371–1382.

Guidelines for the detection of high-risk lipoprotein profiles and the treatment of dyslipoproteinemias. Canadian Lipoprotein Conference Ad Hoc Committee on Guidelines for Dyslipoproteinemias.

PMCID: PMC1451984  PMID: 2190685

Abstract

Elevated plasma levels of cholesterol and triglycerides, low levels of high-density lipoproteins, hypertension, diabetes mellitus, smoking and abdominal obesity are risk factors for coronary heart disease (CHD) and stroke. Because of the preventable threat to life, well-being and productivity from perturbations of plasma lipoproteins (which affect about 60% of adults), we recommend a population-based strategy with public education on diet, exercise and the hazards of smoking and legislation for better food labelling. This should be combined with the medical guidelines we describe to detect and treat those at highest risk for CHD (including about 15% of adults), who merit priority for the medical, dietetic and laboratory services required. Among people aged 40 years or more this includes those with plasma total cholesterol levels greater than 7 mmol/L, fasting triglyceride levels greater than 3 mmol/L or cholesterol level greater than 6 mmol/L when associated with CHD or other risk factors for CHD. For younger people the criteria for highest risk include cholesterol levels greater than 6.5 mmol/L for those aged 30 to 39 years, greater than 6 mmol/L for those aged 20 to 29 and greater than 5 mmol/L for those under age 20.

Full text

PDF
1371

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albers J. J., Brunzell J. D., Knopp R. H. Apoprotein measurements and their clinical application. Clin Lab Med. 1989 Mar;9(1):137–152. [PubMed] [Google Scholar]
  2. Anderson K. M., Castelli W. P., Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987 Apr 24;257(16):2176–2180. doi: 10.1001/jama.257.16.2176. [DOI] [PubMed] [Google Scholar]
  3. Arntzenius A. C., Kromhout D., Barth J. D., Reiber J. H., Bruschke A. V., Buis B., van Gent C. M., Kempen-Voogd N., Strikwerda S., van der Velde E. A. Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial. N Engl J Med. 1985 Mar 28;312(13):805–811. doi: 10.1056/NEJM198503283121301. [DOI] [PubMed] [Google Scholar]
  4. Blankenhorn D. H., Nessim S. A., Johnson R. L., Sanmarco M. E., Azen S. P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987 Jun 19;257(23):3233–3240. [PubMed] [Google Scholar]
  5. Brensike J. F., Levy R. I., Kelsey S. F., Passamani E. R., Richardson J. M., Loh I. K., Stone N. J., Aldrich R. F., Battaglini J. W., Moriarty D. J. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984 Feb;69(2):313–324. doi: 10.1161/01.cir.69.2.313. [DOI] [PubMed] [Google Scholar]
  6. Brewer H. B., Jr, Zech L. A., Gregg R. E., Schwartz D., Schaefer E. J. NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann Intern Med. 1983 May;98(5 Pt 1):623–640. doi: 10.7326/0003-4819-98-5-623. [DOI] [PubMed] [Google Scholar]
  7. Brown W. V., Goldberg I. J., Ginsberg H. N. Treatment of common lipoprotein disorders. Prog Cardiovasc Dis. 1984 Jul-Aug;27(1):1–20. doi: 10.1016/0033-0620(84)90017-3. [DOI] [PubMed] [Google Scholar]
  8. Cambien F., Warnet J. M., Jacqueson A., Ducimetiere P., Richard J. L., Claude J. R. Relation of parental history of early myocardial infarction to the level of apoprotein B in men. Circulation. 1987 Aug;76(2):266–271. doi: 10.1161/01.cir.76.2.266. [DOI] [PubMed] [Google Scholar]
  9. Campeau L., Enjalbert M., Lespérance J., Bourassa M. G., Kwiterovich P., Jr, Wacholder S., Sniderman A. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med. 1984 Nov 22;311(21):1329–1332. doi: 10.1056/NEJM198411223112101. [DOI] [PubMed] [Google Scholar]
  10. Canner P. L., Berge K. G., Wenger N. K., Stamler J., Friedman L., Prineas R. J., Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986 Dec;8(6):1245–1255. doi: 10.1016/s0735-1097(86)80293-5. [DOI] [PubMed] [Google Scholar]
  11. Carlson L. A., Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223(5):405–418. doi: 10.1111/j.0954-6820.1988.tb15891.x. [DOI] [PubMed] [Google Scholar]
  12. Castelli W. P., Doyle J. T., Gordon T., Hames C. G., Hjortland M. C., Hulley S. B., Kagan A., Zukel W. J. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation. 1977 May;55(5):767–772. doi: 10.1161/01.cir.55.5.767. [DOI] [PubMed] [Google Scholar]
  13. Castelli W. P. The triglyceride issue: a view from Framingham. Am Heart J. 1986 Aug;112(2):432–437. doi: 10.1016/0002-8703(86)90296-6. [DOI] [PubMed] [Google Scholar]
  14. Castelli W. P., Wilson P. W., Levy D., Anderson K. Cardiovascular risk factors in the elderly. Am J Cardiol. 1989 May 2;63(16):12H–19H. doi: 10.1016/0002-9149(89)90110-0. [DOI] [PubMed] [Google Scholar]
  15. Davignon J., Gregg R. E., Sing C. F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988 Jan-Feb;8(1):1–21. doi: 10.1161/01.atv.8.1.1. [DOI] [PubMed] [Google Scholar]
  16. Davignon J., Nestruck A. C., Alaupovic P., Bouthillier D. Severe hypoalphalipoproteinemia induced by a combination of probucol and clofibrate. Adv Exp Med Biol. 1986;201:111–125. doi: 10.1007/978-1-4684-1262-8_11. [DOI] [PubMed] [Google Scholar]
  17. Davignon J., Xhignesse M., Roederer G. Identification of the patient at risk in the physician's office and drug management of dyslipoproteinemia. Can J Cardiol. 1988 Jul;4 (Suppl A):36A–47A. [PubMed] [Google Scholar]
  18. De Backer G., Hulstaert F., De Munck K., Rosseneu M., Van Parijs L., Dramaix M. Serum lipids and apoproteins in students whose parents suffered prematurely from a myocardial infarction. Am Heart J. 1986 Sep;112(3):478–484. doi: 10.1016/0002-8703(86)90510-7. [DOI] [PubMed] [Google Scholar]
  19. Duffield R. G., Lewis B., Miller N. E., Jamieson C. W., Brunt J. N., Colchester A. C. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial. Lancet. 1983 Sep 17;2(8351):639–642. doi: 10.1016/s0140-6736(83)92527-8. [DOI] [PubMed] [Google Scholar]
  20. Durrington P. N., Hunt L., Ishola M., Kane J., Stephens W. P. Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction. Br Heart J. 1986 Sep;56(3):206–212. doi: 10.1136/hrt.56.3.206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Fielding C. J. The origin and properties of free cholesterol potential gradients in plasma, and their relation to atherogenesis. J Lipid Res. 1984 Dec 15;25(13):1624–1628. [PubMed] [Google Scholar]
  22. Freedman D. S., Srinivasan S. R., Cresanta J. L., Webber L. S., Berenson G. S. Cardiovascular risk factors from birth to 7 years of age: the Bogalusa Heart Study. Serum lipids and lipoproteins. Pediatrics. 1987 Nov;80(5 Pt 2):789–796. [PubMed] [Google Scholar]
  23. Freedman D. S., Srinivasan S. R., Shear C. L., Franklin F. A., Webber L. S., Berenson G. S. The relation of apolipoproteins A-I and B in children to parental myocardial infarction. N Engl J Med. 1986 Sep 18;315(12):721–726. doi: 10.1056/NEJM198609183151202. [DOI] [PubMed] [Google Scholar]
  24. Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245. doi: 10.1056/NEJM198711123172001. [DOI] [PubMed] [Google Scholar]
  25. Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499–502. [PubMed] [Google Scholar]
  26. Ginsberg H. N., Le N. A., Gibson J. C. Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss. J Clin Invest. 1985 Feb;75(2):614–623. doi: 10.1172/JCI111739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Goldbourt U., Holtzman E., Neufeld H. N. Total and high density lipoprotein cholesterol in the serum and risk of mortality: evidence of a threshold effect. Br Med J (Clin Res Ed) 1985 Apr 27;290(6477):1239–1243. doi: 10.1136/bmj.290.6477.1239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Goldman L., Cook E. F. The decline in ischemic heart disease mortality rates. An analysis of the comparative effects of medical interventions and changes in lifestyle. Ann Intern Med. 1984 Dec;101(6):825–836. doi: 10.7326/0003-4819-101-6-825. [DOI] [PubMed] [Google Scholar]
  29. Goldstein J. L., Schrott H. G., Hazzard W. R., Bierman E. L., Motulsky A. G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973 Jul;52(7):1544–1568. doi: 10.1172/JCI107332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Gotto A. M., Jr, Bierman E. L., Connor W. E., Ford C. H., Frantz I. D., Jr, Glueck C. J., Grundy S. M., Little J. A. Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriocslerosis. Circulation. 1984 May;69(5):1065A–1090A. [PubMed] [Google Scholar]
  31. Grundy S. M., Bilheimer D., Blackburn H., Brown W. V., Kwiterovich P. O., Jr, Mattson F., Schonfeld G., Weidman W. H. Rationale of the diet-heart statement of the American Heart Association. Report of Nutrition Committee. Circulation. 1982 Apr;65(4):839A–854A. [PubMed] [Google Scholar]
  32. Grundy S. M. Cholesterol and coronary heart disease. A new era. JAMA. 1986 Nov 28;256(20):2849–2858. [PubMed] [Google Scholar]
  33. Grundy S. M., Goodman D. W., Rifkind B. M., Cleeman J. I. The place of HDL in cholesterol management. A perspective from the National Cholesterol Educational Program. Arch Intern Med. 1989 Mar;149(3):505–510. [PubMed] [Google Scholar]
  34. Grundy S. M., Vega G. L., Bilheimer D. W. Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia. Ann Intern Med. 1985 Sep;103(3):339–343. doi: 10.7326/0003-4819-103-3-339. [DOI] [PubMed] [Google Scholar]
  35. Henderson B. E., Paganini-Hill A., Ross R. K. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol. 1988 Aug;159(2):312–317. doi: 10.1016/s0002-9378(88)80074-7. [DOI] [PubMed] [Google Scholar]
  36. Hjermann I. Dietary trials for the prevention of coronary heart disease. Eur Heart J. 1987 Aug;8 (Suppl E):39–44. doi: 10.1093/eurheartj/8.suppl_e.39. [DOI] [PubMed] [Google Scholar]
  37. Hjermann I., Velve Byre K., Holme I., Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet. 1981 Dec 12;2(8259):1303–1310. doi: 10.1016/s0140-6736(81)91338-6. [DOI] [PubMed] [Google Scholar]
  38. Hopkins P. N., Williams R. R. A survey of 246 suggested coronary risk factors. Atherosclerosis. 1981 Aug-Sep;40(1):1–52. doi: 10.1016/0021-9150(81)90122-2. [DOI] [PubMed] [Google Scholar]
  39. Hulley S. B., Rhoads G. G. The plasma lipoproteins as risk factors: comparison of electrophoretic and ultracentrifugation results. Metabolism. 1982 Aug;31(8):773–777. doi: 10.1016/0026-0495(82)90074-9. [DOI] [PubMed] [Google Scholar]
  40. Iso H., Jacobs D. R., Jr, Wentworth D., Neaton J. D., Cohen J. D. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989 Apr 6;320(14):904–910. doi: 10.1056/NEJM198904063201405. [DOI] [PubMed] [Google Scholar]
  41. Jacobs D. R., Jr, Barrett-Connor E. Retest reliability of plasma cholesterol and triglyceride. The Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1982 Dec;116(6):878–885. doi: 10.1093/oxfordjournals.aje.a113490. [DOI] [PubMed] [Google Scholar]
  42. Jirkovská A., Válek J., Grafnetter D., Vondra K., Skibová J. Serum lipids and apolipoproteins in families of postinfarction men. Ann Clin Res. 1987;19(1):26–29. [PubMed] [Google Scholar]
  43. Johansson S., Bondjers G., Fager G., Wedel H., Tsipogianni A., Olofsson S. O., Vedin A., Wiklund O., Wilhelmsson C. Serum lipids and apolipoprotein levels in women with acute myocardial infarction. Arteriosclerosis. 1988 Nov-Dec;8(6):742–749. doi: 10.1161/01.atv.8.6.742. [DOI] [PubMed] [Google Scholar]
  44. Kannel W. B., Castelli W. P., Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med. 1979 Jan;90(1):85–91. doi: 10.7326/0003-4819-90-1-85. [DOI] [PubMed] [Google Scholar]
  45. Kannel W. B., Castelli W. P., Gordon T., McNamara P. M. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971 Jan;74(1):1–12. doi: 10.7326/0003-4819-74-1-1. [DOI] [PubMed] [Google Scholar]
  46. Kannel W. B., Neaton J. D., Wentworth D., Thomas H. E., Stamler J., Hulley S. B., Kjelsberg M. O. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. Am Heart J. 1986 Oct;112(4):825–836. doi: 10.1016/0002-8703(86)90481-3. [DOI] [PubMed] [Google Scholar]
  47. Keys A. Food items, specific nutrients, and "dietary" risk. Am J Clin Nutr. 1986 Mar;43(3):477–479. doi: 10.1093/ajcn/43.3.477. [DOI] [PubMed] [Google Scholar]
  48. Knoke J. D., Hawkins D. L. Estimating baseline values of the variable of intervention in a clinical trial. Control Clin Trials. 1985 Jun;6(2):136–145. doi: 10.1016/0197-2456(85)90119-9. [DOI] [PubMed] [Google Scholar]
  49. Kottke B. A., Zinsmeister A. R., Holmes D. R., Jr, Kneller R. W., Hallaway B. J., Mao S. J. Apolipoproteins and coronary artery disease. Mayo Clin Proc. 1986 May;61(5):313–320. doi: 10.1016/s0025-6196(12)61947-8. [DOI] [PubMed] [Google Scholar]
  50. Krauss R. M., Lindgren F. T., Williams P. T., Kelsey S. F., Brensike J., Vranizan K., Detre K. M., Levy R. I. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet. 1987 Jul 11;2(8550):62–66. doi: 10.1016/s0140-6736(87)92734-6. [DOI] [PubMed] [Google Scholar]
  51. Kukita H., Hiwada K., Kokubu T. Serum apolipoprotein A-I, A-II and B levels and their discriminative values in relatives of patients with coronary artery disease. Atherosclerosis. 1984 May-Jun;51(2-3):261–267. doi: 10.1016/0021-9150(84)90173-4. [DOI] [PubMed] [Google Scholar]
  52. Kuksis A., Myher J. J., Geher K., Jones G. J., Breckenridge W. C., Feather T., Hewitt D., Little J. A. Decreased plasma phosphatidylcholine/free cholesterol ratio as an indicator of risk for ischemic vascular disease. Arteriosclerosis. 1982 Jul-Aug;2(4):296–302. doi: 10.1161/01.atv.2.4.296. [DOI] [PubMed] [Google Scholar]
  53. Kuksis A., Roberts A., Thompson J. S., Myher J. J., Geher K. Plasma phosphatidylcholine/free cholesterol ratio as an indicator for atherosclerosis. Arteriosclerosis. 1983 Jul-Aug;3(4):389–397. doi: 10.1161/01.atv.3.4.389. [DOI] [PubMed] [Google Scholar]
  54. Kuo P. T., Hayase K., Kostis J. B., Moreyra A. E. Use of combined diet and colestipol in long-term (7--7 1/2 years) treatment of patients with type II hyperlipoproteinemia. Circulation. 1979 Feb;59(2):199–211. doi: 10.1161/01.cir.59.2.199. [DOI] [PubMed] [Google Scholar]
  55. Kuo P. T., Wilson A. C., Kostis J. B., Moreyra A. B., Dodge H. T. Treatment of type III hyperlipoproteinemia with gemfibrozil to retard progression of coronary artery disease. Am Heart J. 1988 Jul;116(1 Pt 1):85–90. doi: 10.1016/0002-8703(88)90253-0. [DOI] [PubMed] [Google Scholar]
  56. La Rosa J. C. The varying effects of progestins on lipid levels and cardiovascular disease. Am J Obstet Gynecol. 1988 Jun;158(6 Pt 2):1621–1629. doi: 10.1016/0002-9378(88)90200-1. [DOI] [PubMed] [Google Scholar]
  57. Levy R. I. Declining mortality in coronary heart disease. Arteriosclerosis. 1981 Sep-Oct;1(5):312–325. doi: 10.1161/01.atv.1.5.312. [DOI] [PubMed] [Google Scholar]
  58. Mancia G. The need to manage risk factors of coronary heart disease. Am Heart J. 1988 Jan;115(1 Pt 2):240–242. doi: 10.1016/0002-8703(88)90643-6. [DOI] [PubMed] [Google Scholar]
  59. Martin M. J., Hulley S. B., Browner W. S., Kuller L. H., Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 1986 Oct 25;2(8513):933–936. doi: 10.1016/s0140-6736(86)90597-0. [DOI] [PubMed] [Google Scholar]
  60. Mendez I., Hachinski V., Wolfe B. Serum lipids after stroke. Neurology. 1987 Mar;37(3):507–511. doi: 10.1212/wnl.37.3.507. [DOI] [PubMed] [Google Scholar]
  61. Miettinen M., Turpeinen O., Karvonen M. J., Elosuo R., Paavilainen E. Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes. A twelve-year clinical trial in men and women. Lancet. 1972 Oct 21;2(7782):835–838. doi: 10.1016/s0140-6736(72)92208-8. [DOI] [PubMed] [Google Scholar]
  62. Miller G. J., Miller N. E. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975 Jan 4;1(7897):16–19. doi: 10.1016/s0140-6736(75)92376-4. [DOI] [PubMed] [Google Scholar]
  63. Nestel P. J., Fidge N. H., Tan M. H. Increased lipoprotein-remnant formation in chronic renal failure. N Engl J Med. 1982 Aug 5;307(6):329–333. doi: 10.1056/NEJM198208053070601. [DOI] [PubMed] [Google Scholar]
  64. Newman W. P., 3rd, Freedman D. S., Voors A. W., Gard P. D., Srinivasan S. R., Cresanta J. L., Williamson G. D., Webber L. S., Berenson G. S. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med. 1986 Jan 16;314(3):138–144. doi: 10.1056/NEJM198601163140302. [DOI] [PubMed] [Google Scholar]
  65. Nikkilä E. A., Viikinkoski P., Valle M., Frick M. H. Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study. Br Med J (Clin Res Ed) 1984 Jul 28;289(6439):220–223. doi: 10.1136/bmj.289.6439.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. O'Leary T. J., Simo I. E., Kanigsberg N., Walker J., Goodall J. C., Ooi T. C. Changes in serum lipoproteins and high-density lipoprotein composition during isotretinoin therapy. Clin Invest Med. 1987 Jul;10(4):355–360. [PubMed] [Google Scholar]
  67. Plunkett E. R. Contraceptive Steroids, age, and the cardiovascular system. Am J Obstet Gynecol. 1982 Mar 15;142(6 Pt 2):747–751. doi: 10.1016/s0002-9378(16)32482-6. [DOI] [PubMed] [Google Scholar]
  68. Puska P., Salonen J. T., Nissinen A., Tuomilehto J., Vartiainen E., Korhonen H., Tanskanen A., Rönnqvist P., Koskela K., Huttunen J. Change in risk factors for coronary heart disease during 10 years of a community intervention programme (North Karelia project). Br Med J (Clin Res Ed) 1983 Dec 17;287(6408):1840–1844. doi: 10.1136/bmj.287.6408.1840. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Reardon M. F., Nestel P. J., Craig I. H., Harper R. W. Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation. 1985 May;71(5):881–888. doi: 10.1161/01.cir.71.5.881. [DOI] [PubMed] [Google Scholar]
  70. Rifkind B. M., Segal P. Lipid Research Clinics Program reference values for hyperlipidemia and hypolipidemia. JAMA. 1983 Oct 14;250(14):1869–1872. [PubMed] [Google Scholar]
  71. Roberts L. Measuring cholesterol is as tricky as lowering it. Science. 1987 Oct 23;238(4826):482–483. doi: 10.1126/science.3659924. [DOI] [PubMed] [Google Scholar]
  72. Shaper A. G., Cook D. G., Walker M., Macfarlane P. W. Prevalence of ischaemic heart disease in middle aged British men. Br Heart J. 1984 Jun;51(6):595–605. doi: 10.1136/hrt.51.6.595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet. 1969 Dec 27;2(7635):1380–1382. doi: 10.1016/s0140-6736(69)90930-1. [DOI] [PubMed] [Google Scholar]
  74. Slattery M. L., Randall D. E. Trends in coronary heart disease mortality and food consumption in the United States between 1909 and 1980. Am J Clin Nutr. 1988 Jun;47(6):1060–1067. doi: 10.1093/ajcn/47.6.1060. [DOI] [PubMed] [Google Scholar]
  75. Sniderman A. D. Apolipoprotein B and apolipoprotein AI as predictors of coronary artery disease. Can J Cardiol. 1988 Jul;4 (Suppl A):24A–30A. [PubMed] [Google Scholar]
  76. Sniderman A. D., Wolfson C., Teng B., Franklin F. A., Bachorik P. S., Kwiterovich P. O., Jr Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med. 1982 Dec;97(6):833–839. doi: 10.7326/0003-4819-97-6-833. [DOI] [PubMed] [Google Scholar]
  77. Sniderman A., Teng B., Genest J., Cianflone K., Wacholder S., Kwiterovich P., Jr Familial aggregation and early expression of hyperapobetalipoproteinemia. Am J Cardiol. 1985 Feb 1;55(4):291–295. doi: 10.1016/0002-9149(85)90363-7. [DOI] [PubMed] [Google Scholar]
  78. Stamler J., Wentworth D., Neaton J. D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986 Nov 28;256(20):2823–2828. [PubMed] [Google Scholar]
  79. Stark R. M. The atherogenic risk of antihypertensive therapy. Am J Med. 1988 Jan 29;84(1B):86–88. [PubMed] [Google Scholar]
  80. Steiner G., Schwartz L., Shumak S., Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation. 1987 Jan;75(1):124–130. doi: 10.1161/01.cir.75.1.124. [DOI] [PubMed] [Google Scholar]
  81. Thompson G. R. Evidence that lowering serum lipids favourably influences coronary heart disease. Q J Med. 1987 Feb;62(238):87–95. [PubMed] [Google Scholar]
  82. Utermann G. The mysteries of lipoprotein(a). Science. 1989 Nov 17;246(4932):904–910. doi: 10.1126/science.2530631. [DOI] [PubMed] [Google Scholar]
  83. Van Stiphout W. A., Hofman A., Kruijssen H. A., Vermeeren R., Groot P. H. Is the ratio of apo B/apo A-I an early predictor of coronary atherosclerosis? Atherosclerosis. 1986 Nov;62(2):179–182. doi: 10.1016/0021-9150(86)90065-1. [DOI] [PubMed] [Google Scholar]
  84. Vergani C., Bettale G. Familial hypo-alpha-lipoproteinemia. Clin Chim Acta. 1981 Jul 18;114(1):45–52. doi: 10.1016/0009-8981(81)90226-6. [DOI] [PubMed] [Google Scholar]
  85. Weinstein L. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient. Obstet Gynecol. 1987 Jun;69(6):929–932. [PubMed] [Google Scholar]
  86. Wilson P. W., Abbott R. D., Castelli W. P. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 1988 Nov-Dec;8(6):737–741. doi: 10.1161/01.atv.8.6.737. [DOI] [PubMed] [Google Scholar]
  87. Wolfe B. M., Huff M. W. Effects of combined estrogen and progestin administration on plasma lipoprotein metabolism in postmenopausal women. J Clin Invest. 1989 Jan;83(1):40–45. doi: 10.1172/JCI113882. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES